Antidepressants

#Antidepressants #Depression #Drug targets #Korea University #Major depressive disorder #Neuroscience

New evidence revives abandoned depression drug target

New research has revealed that structurally novel neurokinin-1 receptor (NK1R) inhibitors reduce depressive-like behaviour and brain inflammation in mice.  For decades, scientists have investigated the NK1R as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs… Read More

#Editor's Choice #Editor's Pick #News

Mental health concept
#Antidepressants #Gut-brain interaction #Mental health #Neuroscience

A promising new target for mental health

DDW Editor Reece Armstrong speaks to Kara Margolis, MD, Director of the NYU Pain Research Center and Associate Professor at NYU College of Dentistry and NYU Grossman School of Medicine, and Mark Ansorge, Associate Professor of clinical neurobiology at Columbia University about recent research highlighting the importance between the gut… Read More

#Exclusive Content

gut epithelium
#Antidepressants #Anxiety disorder #Depression #Gut-brain interaction #Pregnancy

Could the gut epithelium be a new target for antidepressants?

Researchers have discovered new connections between the gut and brain that hold promise for more targeted treatments for depression and anxiety.  The findings could also help prevent digestive issues in children by limiting the transmission of antidepressants during pregnancy.   The study,… Read More

#News #Trending News

#Antidepressants #Neurology #Neuropsychiatric disorders #Neuroscience #Psychedelics #Psychiatry

Reshaping neuropsychiatry

Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More

#Exclusive Content

Patient holding pill in hand
#Antidepressants #Depression #Major depressive disorder #MIRA Pharmaceuticals #MIRALOGX

Partners develop oral ketamine-based antidepressant for home use

MIRA Pharmaceuticals and MIRALOGX have formed a new partnership to develop and commercialise oral ketamine analog Ketamir-2, hoping to change the landscape of depressive disorder treatments. Ketamir-2 is a patent-pending compound under investigation to potentially deliver ultra-rapid antidepressant effects as early as four hours after dosing. After making its scientific… Read More

#Business & Investment #News

Neuron
#Antidepressants #Biomarkers #Depression #Gate Neurosciences #Neuroscience #Phase I trial

Phase I clinical trial validates qEEG biomarker in CNS disorders

Gate Neurosciences has announced positive topline quantitative EEG (qEEG) biomarker and safety results from its Phase I multiple ascending dose study of apimostinel in healthy volunteers. The results demonstrated a dose-dependent increase in qEEG pharmacodynamic biomarkers of NMDA receptor target activation from baseline, compared with subjects… Read More

#News

Sciatic nerve
#Antidepressants #Boston University #Chronic pain #Icahn School of Medicine #RNA sequencing

Could antidepressant tianeptine treat chronic pain?

Scientists from Boston University have published evidence that the atypical antidepressant tianeptine potentially provides rapid and lasting neuropathic pain relief with a low risk of addiction. The researchers from Boston University Chobanian & Avedisian School of Medicine in collaboration with the Icahn School of Medicine, Columbia… Read More

#Editor's Choice #News

Human brain
#AlzeCure Pharma #Antidepressants #Depression #Preclinical investigations #Psychiatry

Preclinical study proves antidepressant effects of drug

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various… Read More

#Editor's Choice #News

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

Hormones in the brain concept
#Antidepressants #Depression #Evecxia Therapeutics #Major depressive disorder #Phase I trial #Psychiatry

New adjunctive antidepressant elevates serotonin in Phase I trial

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. The company is also planning a Phase II adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a… Read More

#News

Dr Yue Wang and Professor Jianhua Guo
#Antibiotic resistance #Antibiotics #Antidepressants #Antimicrobial resistance (AMR) #Psychiatry

Common antidepressants increase antibiotic resistance

Researchers have found a range of commonly prescribed antidepressants can increase bacteria’s resistance to antibiotic medications. A study led by Professor Jianhua Guo from University of Queensland’s Australian Centre for Water and Environmental Biotechnology focused on prescription drugs used to treat depressive disorders, anxiety disorders, and other psychological… Read More

#News

Neurons in the brain
#Antidepressants #Interview #Major depressive disorder #Neuropsychiatric disorders #Neuroscience #Precision medicine #Precision psychiatry #Psychiatry

Precision psychiatry: Transforming therapeutics for CNS disorders

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding… Read More

#Exclusive Content